Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer

被引：0
作者：
Jing Deng
Anthony Letai
机构：
[1] Dana-Farber Cancer Institute,Department of Medical Oncology
来源：
Breast Cancer Research | / 15卷
关键词：
Breast Cancer; Estrogen Receptor; Tamoxifen; Chronic Lymphocytic Leukemia; Prime Cancer Cell;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The B-cell lymphoma/leukemia 2 protein (BCL-2) may help many types of cancers to evade cell death. However, identifying exactly where this is the case is a challenge. ABT-199 is a small molecule that selectively inhibits BCL-2, which is currently in clinical trials in lymphoid malignancies. While inhibiting BCL-2 by itself can cause cell death in hematopoietic tumors, single-agent activity is harder to observe in solid tumors. Combining ABT-199 with tamoxifen, the standard endocrine therapy for estrogen receptor-positive breast cancers, 85% of which have BCL-2 expression, represents a new strategy to prime cancer cells for apoptosis and elicit better cancer cell death responses.
引用
收藏
相关论文
共 203 条
  • [1] Sørlie T(2001)Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 98 10869-10874
  • [2] Perou CM(2004)Mechanisms of tamoxifen resistance Endocr Relat Cancer 11 643-658
  • [3] Tibshirani R(2009)Biological determinants of endocrine resistance in breast cancer Nat Rev Cancer 9 631-643
  • [4] Aas T(2013)Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer Cancer Cell 24 120-129
  • [5] Geisler S(2005)An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 435 677-681
  • [6] Johnsen H(2008)ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Res 68 3421-3428
  • [7] Hastie T(2012)Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease J Clin Oncol 30 488-496
  • [8] Eisen MB(2010)Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity Lancet Oncol 11 1149-1159
  • [9] van de Rijn M(2013)ABT-199: taking dead aim at BCL-2 Cancer Cell 23 139-141
  • [10] Jeffrey SS(2013)ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets Nat Med 19 202-208
12345678910